Compounds for use in the treatment of cancer or viral infections

A pharmaceutically acceptable salt of a compound having the following A-3:

• wherein,
• R3 is hydroxyalkyl, hydroxyalkoxyalkyl, or hydroxypoly(alkoxy)alkyl;
• each of X mad Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, bromo, chloro, fluoro, nitro, or amino;
• and
• n is 1, 2, or 3.

A prodrug of a compound having the following formula A-3:

• wherein,
• R3 is haloalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkyl, substituted or unsubstituted benzyl, hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;
• when X is hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, bromo, chloro, fluoro, nitro, or amino;
• and Y is alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, bromo, chloro, fluoro, or amino;
• or
• R3 is haloalkenyl, cycloalkyl, cycloalkaalkyl, heterocycloalkyl, heterocycloalkalkyl, unsubstituted benzyl, hydroxyalkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;
• when each of X and Y is hydrogen;
• and
• n is 1, 2, or 3.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of the following formula:

• wherein,
• R1 is —COOR3;
• R3 is hydroxyalkoxyalkyl, or hydroxypoly(alkoxy)alkyl;
• each of X and Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, halogen, nitro, or amino;
• and
• n is 1, 2, or 3;
• and, a pharmaceutically acceptable carrier.

A pharmaceutically composition comprising a therapeutically effective amount of a compound of the following formula:

• wherein,
• R1 is —COOR3;
• R3 is haloalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkyl, substituted or unsubstituted benzyl, hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;
• each of X and Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, halogen, nitro, or amino;
• and
• n is 1, 2, or 3;
• and, a pharmaceutically acceptable carrier wherein the carrier is in the form of a liposome delivery system.

A pharmaceutically composition comprising a therapeutically effective amount of a compound of the following formula:

• wherein,
• R1 is —COOR3;
• R3 is hydroxyalkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl;
• each of X and Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, halogen, nitro, or amino;
• and
• n is 1, 2, or 3;
• and, a pharmaceutically acceptable carrier wherein said compound is micronized and said composition is suitable for administration by injection.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of the following formula:

• wherein,
• R1 is —COOR3;
• R3 is haloalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkyl, substituted or unsubstituted benzyl, hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;
• each of X and Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, halogen, nitro, or amino;
• and
• n is 1, 2, or 3;
• and, a pharmaceutically acceptable carrier wherein said carrier is a soluble polymer and the compound is coupled to the soluble polymer.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of the following formula:

• wherein,
• R1 is —COOR3;
• R3 is haloalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkyl, substituted or unsubstituted benzyl, hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;
• each of X and Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, halogen, nitro, or amino;
• and
• n is 1, 2, or 3;
• and, a pharmaceutically acceptable carrier wherein said carrier is a biodegradable polymer and the compound is coupled to the biodegradable polymer.